FDA Orange Book · active-ingredient family
Piperazine citrate
Piperazine citrate is approved as 3 brand and 5 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:ANTEPAR · NDA 009102
3
Brand (NDA)
5
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · syrup, tablet
Generic (ANDA) products (5)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| PIPERAZINE CITRATE | ALPHARMA US PHARMS | ANDA 080774 | — | Approved Prior to Jan 1, 1982 | |
| PIPERAZINE CITRATE | LANNETT | ANDA 080963 | — | Approved Prior to Jan 1, 1982 | |
| PIPERAZINE CITRATE | LUITPOLD | ANDA 080671 | — | Approved Prior to Jan 1, 1982 | |
| VERMIDOL | SOLVAY | ANDA 080992 | — | Approved Prior to Jan 1, 1982 | |
| PIPERAZINE CITRATE | IMPAX LABS | ANDA 080874 | — | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Piperazine citrate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
